# V35 Queue: Autonomous One-Hour Self-Chaining Exploration Block

Block start UTC: 2026-06-07T16:37:36Z
Target block end UTC: 2026-06-07T17:37:36Z

## Iteration Log

### Iteration 1

- Start UTC: 2026-06-07T16:37:36Z
- Status: completed
- Item selected: EBV/IFN APC imprint grounding.
- Note: OpenGWAS verified; `SAP_AI_CORE_API_KEY` present.
- Result: needs data / not currently testable as EBV-specific. MS-SLE rg and
  V26 IFN/APC structure support prioritization, but current held data lack
  EBV-serostatus/viral-load stratification and EBV-latency genes (`EBNA1`,
  `LMP1`, `LMP2A`) in usable expression panels.

### Iteration 2

- Start UTC: 2026-06-07T16:40:04Z
- Status: completed
- Item selected: Postpartum APC-arm imbalance, MS-specificity.
- Note: Scout reachable MS postpartum/pregnancy immune data; if unavailable,
  stress-test cross-disease heterogeneity and specify exact cohort need.
- Result: partially grounded / MS postpartum data still missing. Local
  `GSE17410/GSE17449` has MS PBMC before/during pregnancy and relapse-vs-free
  description, but no postpartum timepoints and no local normalized expression
  matrix for immediate module scoring. Cross-disease heterogeneity shows
  CD64-shift dominated decoupling in healthy/SLE/SNRA and HLA-II-rebound
  dominated decoupling in SPRA.

### Iteration 3

- Start UTC: 2026-06-07T16:41:26Z
- Status: completed
- Item selected: Complement/lipid progressive axis.
- Note: Test against reachable progressive/chronic-active lesion data or report
  exact data gap.
- Result: partially grounded. Local GSE180759 supports a lipid-repair immune
  component at chronic-active lesion edge, but complement/phagocytosis and
  IFN/HLA/APC are not uniquely elevated versus control white matter in the quick
  module summary. Needs donor-aware pathology comparison.

### Iteration 4

- Start UTC: 2026-06-07T16:44:32Z
- Status: completed
- Item selected: T/B compartment remodeling gate.
- Note: Test on existing single-cell/compartment data and null-test where
  feasible.
- Result: supported but small-n. Exact V23 tofacitinib compartment scores show
  T/B-like compartments with mean locked-rule AUC `0.975` versus non-T/B mean
  `0.817`; exact patient-label permutation of the T/B-minus-non-T/B gap gives
  p `0.0635` over `126` label assignments.

### Iteration 5

- Start UTC: 2026-06-07T16:46:10Z
- Status: completed
- Item selected: Lysosomal APC-processing bottleneck.
- Note: Test cathepsin/V-ATPase/lysosomal-flux modules in APC/immune data and
  report whether existing perturbation data is sufficient.
- Result: reframed. V26 Mixscale perturbation modules support a coupled
  lysosomal APC arm (`gilt_lysosomal_apc` vs `ifn_apc` Spearman `0.902`,
  permutation p `0.00010`; vs `hla_ii_apc` Spearman `0.547`, p `0.0066`), but
  do not prove a functional antigen-processing bottleneck.

### Iteration 6

- Start UTC: 2026-06-07T16:48:03Z
- Status: completed
- Item selected: Metabolic/sterol setpoint.
- Note: Ground against existing metabolic module data and relate to V32
  immune-tone confounding.
- Result: supported as context axis, not intervention-grade. V32
  metabolic/inflammatory/STAT1 joint adjustment attenuates the monitoring
  signal (AUC `0.811` to `0.656`); ST003328 shows higher cholesterol in
  progressive MS-derived iNSC models and simvastatin lowering; GSE180759 shows
  modest cholesterol-synthesis transcript elevation at chronic-active lesion
  edge immune cells.

### Iteration 7

- Start UTC: 2026-06-07T16:52:14Z
- Status: completed
- Item selected: Two-lineage cross-examination of grounded hypotheses.
- Note: Ask Claude and Gemini for fatal weakness/strongest test of the grounded
  V35 shortlist; use as prioritization only, not evidence.
- Result: completed. Claude and Gemini converged on T/B gate replication as the
  highest-priority validation need; identified postpartum MS as data-acquisition
  blocked; and selected donor-aware complement/lipid lesion-edge testing as the
  highest-priority executable hardening step.

### Iteration 8

- Start UTC: 2026-06-07T16:54:30Z
- Status: completed
- Item selected: Donor-aware complement/lipid progressive-axis hardening.
- Note: Execute the convergent two-lineage next test on local GSE180759 using
  donor/case-aware summaries where metadata supports it.
- Result: downgraded. Donor-level immune-cell aggregation removes the clean
  chronic-active edge claim: complement is not elevated and lipid repair is only
  weak/directional, not statistically hardened.

### Iteration 9

- Start UTC: 2026-06-07T16:57:06Z
- Status: in_progress
- Item selected: T/B gate fragility check.
- Note: Stress-test the n=9 tofacitinib T/B signal for leave-one-patient and
  W48 timepoint leverage.

## Backlog

| Priority | Item | Status | Current Result / Resume Note |
|---:|---|---|---|
| 1 | EBV/IFN APC imprint | done | Needs EBV-stratified MS/SLE B-cell/APC data; current held summaries cannot separate EBV imprint from generic IFN/APC. |
| 2 | Postpartum APC-arm imbalance, MS-specificity | done | Partially grounded; true MS postpartum relapse-window data missing. |
| 3 | Complement/lipid progressive axis | done | Partially grounded; lipid-repair immune component at chronic-active edge, complement not yet uniquely supported. |
| 4 | T/B compartment remodeling gate | done | Supported but small-n; T/B-like AUC advantage p=0.0635 by exact patient-label permutation in n=9 tofacitinib cohort. |
| 5 | Lysosomal APC-processing bottleneck | done | Reframed as coupled lysosomal APC arm; functional bottleneck remains unproven without lysosomal flux/HLA-peptidomics. |
| 6 | Metabolic/sterol setpoint | done | Supported as context axis; not intervention-grade without APC-resolved lipidomics/perturbation. |
| 7 | Two-lineage cross-examination of grounded hypotheses | done | Both lineages converged on T/B replication, postpartum data acquisition, and donor-aware complement/lipid hardening. |
| 8 | Donor-aware complement/lipid progressive-axis hardening | done | Downgraded: donor-level test supports lipid-repair context only; complement not supported. |
| 9 | T/B gate fragility check | in_progress | Stress-test n=9 tofacitinib result for influential patients/timepoints. |

## Timing Rule

Each iteration must append its measured start and end UTC from `date -u`.
Continue chaining until cumulative measured active time is at least 60 minutes,
unless all backlog items are done/blocked or external termination occurs.
